Suppr超能文献

低恶性外周T细胞非霍奇金淋巴瘤:25例多形性小细胞淋巴瘤、淋巴上皮样细胞( Lennert 氏)淋巴瘤和T区淋巴瘤患者的前瞻性研究。基尔淋巴瘤研究组

Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.

作者信息

Siegert W, Nerl C, Engelhard M, Brittinger G, Tiemann M, Parwaresch R, Heinz R, Huhn D

机构信息

Universitätsklinikum Rudolf Virchow, Abteilung für Innere Medizin mit Schwerpunkt Hämatologie und Onkologie, Freie Universität Berlin, Germany.

出版信息

Br J Haematol. 1994 Jul;87(3):529-34. doi: 10.1111/j.1365-2141.1994.tb08308.x.

Abstract

Peripheral T-cell lymphomas comprise a heterogenous group of low- and high-grade malignancies differing in their histopathological appearance and also in clinical and prognostic aspects. We prospectively studied 25 patients with low-grade peripheral T-cell lymphomas: pleomorphic, small cell lymphoma (PSC) (n = 9), lymphoepitheloid (Lennert's) lymphoma (LEL) (n = 12) and T-zone lymphoma (TZL) (n = 4). The median patient age was 55 years (range 19-75 years); the male to female ratio was 1.5. 13 patients (52%) had limited stages (I+II), 12 patients (48%) had advanced disease (stage III+IV). 21 patients received the COPBLAM/IMVP-16 regimen. Two patients received more intensive treatments; two received less intensive therapy. Complete remissions were achieved in 16/25 patients (64%). The median observation time of surviving patients was 30 months (range 5-72 months). The actuarial overall survival and event-free survival at 2 years of 21 patients receiving COPBLAM/IMVP-16 were 69% and 35%, respectively. Intensive chemotherapy led to complete remissions in about 60% of the patients and to long-term disease-free survival for one-third. The observed clinical courses illustrate the aggressive nature of PSC, LEL and TZL.

摘要

外周T细胞淋巴瘤是一组异质性的低度和高度恶性肿瘤,其组织病理学表现、临床和预后情况各不相同。我们前瞻性地研究了25例低度外周T细胞淋巴瘤患者:多形性小细胞淋巴瘤(PSC)(n = 9)、淋巴上皮样( Lennert 氏)淋巴瘤(LEL)(n = 12)和T细胞区淋巴瘤(TZL)(n = 4)。患者的中位年龄为55岁(范围19 - 75岁);男女比例为1.5。13例患者(52%)处于局限期(I + II期),12例患者(48%)患有晚期疾病(III + IV期)。21例患者接受了COPBLAM/IMVP - 16方案治疗。2例患者接受了更强化的治疗;2例接受了强度较低的治疗。25例患者中有16例(64%)实现了完全缓解。存活患者的中位观察时间为30个月(范围5 - 72个月)。接受COPBLAM/IMVP - 16治疗的21例患者在2年时的精算总生存率和无事件生存率分别为69%和35%。强化化疗使约60%的患者实现了完全缓解,并使三分之一的患者获得了长期无病生存。观察到的临床病程说明了PSC、LEL和TZL的侵袭性本质。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验